Aurinia Pharmaceuticals (AUPH) Work In Process (2023 - 2026)

Aurinia Pharmaceuticals has reported Work In Process for 4 years, with the latest figure at $41.4 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process fell 0.79% year-over-year to $41.4 million; the trailing twelve-month figure through Mar 2026 stood at $41.4 million (down 0.79% YoY), and the FY2025 full-year result was $44.7 million, up 21.93% from the prior year.
• Work In Process for Q1 2026 stood at $41.4 million, down from $44.7 million in the prior quarter.
• The five-year high for Work In Process was $44.7 million in Q4 2025, with the low at $36.6 million in Q4 2024.
• Historically, Work In Process has averaged $41.1 million across 4 years, with a median of $41.7 million in 2025.
• Annual changes were most pronounced in 2024 — Work In Process dropped 2.01% — and 2025, when it rose 21.93%.
• Aurinia Pharmaceuticals' Work In Process stood at $37.4 million in 2023, then retreated by 2.01% to $36.6 million in 2024, then increased by 21.93% to $44.7 million in 2025, then retreated by 7.24% to $41.4 million in 2026.
• The last three Work In Process figures came in at $41.4 million (Q1 2026), $44.7 million (Q4 2025), and $42.6 million (Q3 2025), per Business Quant data.